CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Current Assets:
Cash and cash equivalents ($81,776 and $98,277 restricted at December 31, 2016 and September 30, 2017, respectively)	$ 504,764	$ 304,508
Accounts receivable, less allowance of $5,644 and $8,657 at December 31, 2016 and September 30, 2017, respectively	622,431	606,764
Short-term investments ($227,795 and $238,869 restricted at December 31, 2016 and September 30, 2017, respectively)	312,902	297,493
Pharmaceutical inventory	48,941	58,995
Other current assets ($38,785 and $23,140 restricted at December 31, 2016 and September 30, 2017, respectively)	52,896	51,507
Total Current Assets	1,541,934	1,319,267
Property and equipment, net	161,437	172,524
Long-term investments ($6,306 and $10,575 restricted at December 31, 2016 and September 30, 2017, respectively)	10,575	7,760
Deferred income taxes	5,249	3,125
Other long-term assets	40,621	12,725
Goodwill	745,947	742,054
Other intangible assets, net	156,351	186,232
Total Assets	2,662,114	2,443,687
Current Liabilities:
Accounts payable	66,530	95,635
Accrued liabilities	173,701	202,176
Short-term contingent consideration	8,875	9,354
Medical claims payable	213,692	184,136
Other medical liabilities	193,881	197,856
Current debt and capital lease obligations	19,231	403,693
Total Current Liabilities	675,910	1,092,850
Long-term debt and capital lease obligations	745,543	214,686
Tax contingencies	14,348	13,981
Long-term contingent consideration	615	1,799
Deferred credits and other long-term liabilities	18,290	15,882
Total Liabilities	1,454,706	1,339,198
Redeemable non-controlling interest	4,704	4,770
STOCKHOLDERS' EQUITY
Preferred stock, par value $.01 per share Authorized—10,000 shares at December 31, 2016 and September 30, 2017-Issued and outstanding-none
Ordinary common stock, par value $.01 per share Authorized-100,000 shares at December 31, 2016 and September 30, 2017-Issued and outstanding-51,993 and 23,517 shares at December 31, 2016, respectively, and 52,723 and 24,042 shares at September 30, 2017, respectively	527	520
Other Stockholders' Equity:
Additional paid-in capital	1,248,993	1,186,283
Retained earnings	1,344,986	1,289,288
Accumulated other comprehensive loss	(148)	(175)
Treasury stock, at cost, 28,476 and 28,681 shares at December 31, 2016 and September 30, 2017, respectively	(1,391,654)	(1,376,197)
Total Stockholders' Equity	1,202,704	1,099,719
Total Liabilities, Redeemable Non-Controlling Interest and Stockholders' Equity	$ 2,662,114	$ 2,443,687